About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Cleveland | 19,775 Studies Near You | Clareo Health

Clinical Trials LocationsCleveland

Clinical Trials in Cleveland

Discover 19,775 clinical trials near Cleveland, Ohio. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2161-2180 of 19,775 trials

Active Not RecruitingPhase 1< 1 mile

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT05891171

The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

Advanced CancerAdvanced MalignanciesBladder Cancer+9 more

Arcus Biosciences, Inc.40 participantsStarted Oct 2023

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Lake City, Florida, United States +12 more locations

COMPLETEDPhase 3< 1 mile

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

NCT05583526

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Stable Nonsegmental VitiligoActive Nonsegmental Vitiligo

Pfizer607 participantsStarted Dec 2022

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Encinitas, California, United States +112 more locations

Find Trials by Condition in Cleveland

Breast Cancerin Cleveland Lung Cancerin Cleveland Prostate Cancerin Cleveland Colorectal Cancerin Cleveland Melanomain Cleveland Leukemiain Cleveland Lymphomain Cleveland Pancreatic Cancerin Cleveland Ovarian Cancerin Cleveland Brain Cancerin Cleveland

Data from ClinicalTrials.govTerms

Not Yet RecruitingNA< 1 mile

Parent-Mediated Telehealth Intervention for Insomnia in Young Autistic Children

NCT07435740

This study will evaluate the efficacy of a structured parent-mediated behavioral intervention called Sleep Parent Treatment (SPT) for insomnia in autistic children ages 3 to 7 years 11 months, compared to another behavioral intervention called Sleep Parent Education (SPE). Eligible children will be randomly assigned to either the SPT or SPE intervention for 10 weeks.

Emory University180 participantsStarted Mar 2026

Atlanta, Georgia, United States • Cleveland, Ohio, United States • Columbus, Ohio, United States

RECRUITINGPhase 3< 1 mile

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT03633708

This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.

Secondary HyperparathyroidismChronic Kidney Disease

Amgen56 participantsStarted Apr 2019

Los Angeles, California, United States • Aurora, Colorado, United States • Kansas City, Missouri, United States +40 more locations

Active Not RecruitingPhase 1< 1 mile

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

NCT03434769

The purpose of this study is to determine if it is possible to treat your cancer with a new type of T cell-based immunotherapy (therapy that uses your immune system to treat the cancer). T cells are a type of white blood cell that helps the body fight infections. This treatment uses T cells already present within your body that have been modified outside of the body and returned to target your cancer. This type of treatment is sometimes referred to as adoptive cell transfer (ACT). In this study the specific type of cells that will be used is called chimeric antigen receptor T cells (CAR T cells). Another purpose of this study is to learn about the side effects and toxicities related to this treatment.

Non-Hodgkin Lymphoma

Benjamin Tomlinson31 participantsStarted Jul 2018

St Louis, Missouri, United States • Cleveland, Ohio, United States

COMPLETEDPhase 3< 1 mile

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00003809

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether cisplatin plus monoclonal antibody therapy is more effective than cisplatin alone for metastatic or recurrent head and neck cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of cisplatin with or without monoclonal antibody in treating patients who have metastatic or recurrent head and neck cancer.

Head and Neck Cancer

Eastern Cooperative Oncology GroupStarted Aug 1999

Scottsdale, Arizona, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +73 more locations

COMPLETEDPhase 1/2< 1 mile

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

NCT04526106

This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in patients with unresectable or metastatic cholangiocarcinoma (CCA) and other solid tumors. The study consists of 4 parts: a dose escalation (Part 1), a dose expansion (Part 2), and an extension (Part 3) and a rollover (Part 4).

FGFR2 AmplificationFGFR2 Gene MutationFGFR2 Gene Fusion/Rearrangement+5 more

Elevar Therapeutics490 participantsStarted Sep 2020

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +45 more locations

RECRUITINGPhase 3< 1 mile

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

NCT03067181

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Childhood Extracranial Germ Cell TumorExtragonadal Embryonal CarcinomaGerm Cell Tumor+27 more

Children's Oncology Group1,780 participantsStarted May 2017

Birmingham, Alabama, United States • Mobile, Alabama, United States • Anchorage, Alaska, United States +627 more locations

RECRUITINGPhase 312 miles

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07184996

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 35 weeks with: * Screening period * 12-week Sub-Study 1 (Single-Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction) * 12-week Sub-Study 3 (Extended Induction for non-responders) * 45 days follow-up visit for participants who do not enroll into the maintenance study (EFC18359) The treatment duration will be up to 12 weeks in each sub-study. The number of scheduled on-site visits will be up to 8 for the Sub-Study 1 and Sub Study 2 or a maximum of 15 visits for participants completing extended induction.

Ulcerative Colitis

Sanofi980 participantsStarted Oct 2025

Peoria, Arizona, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +85 more locations

RECRUITINGPhase 1/2115 miles

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

NCT06888921

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously * Undergo various tests and procedures to monitor general health throughout the trial including physical examinations, vital sign measurements (heart rate, blood pressure, breathing, and body temperature), weight measurements, electrocardiography (ECG), blood and urine tests and pregnancy tests if relevant. * Undergo various tests and procedures to assess disease response throughout the trial including tumor imaging by CT scans or MRI to assess the tumor, its location, and size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh biopsy if feasible, to evaluate tumor response to treatment and to measure levels of tumor markers,

Ovarian CancerOvarian Cancer Recurrent

Compugen Ltd60 participantsStarted Jul 2025

Augusta, Georgia, United States • Chicago, Illinois, United States • Warrenville, Illinois, United States +25 more locations

Enrolling By InvitationNA118 miles

Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years

NCT07217249

This multi-center clinical trial is designed to assess the association of diabetes in a cornea donor with transplant success and loss of endothelial cells 5 years following Descemet membrane endothelial keratoplasty (DMEK). Study eyes are assigned to receive either a cornea from a donor without diabetes or a cornea from a donor with diabetes in a masked fashion.

Fuchs Endothelial Corneal DystrophyCorneal Endothelial Decompensation

Case Western Reserve University570 participantsStarted Dec 2025

Atlanta, Georgia, United States • Indianapolis, Indiana, United States • Iowa City, Iowa, United States +11 more locations

RECRUITINGPhase 1/2126 miles

SMP-3124LP in Adults With Advanced Solid Tumors

NCT06526819

An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

Sumitomo Pharma America, Inc.120 participantsStarted Aug 2024

Los Angeles, California, United States • Denver, Colorado, United States • Chicago, Illinois, United States +7 more locations

RECRUITINGNA126 miles

Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study

NCT07114718

Starlight Cardiovascular, Inc. is sponsoring a prospective, multi-center, study to evaluate safety and effectiveness of the Lifeline Ductus Arteriosus Stent System. The study device is a stent that is designed to maintain patency of the Ductus Arteriosus for children who need blood flow through that part of the heart.

Congenital Heart DiseaseCongenital Heart Disease (CHD)

Starlight Cardiovascular Inc35 participantsStarted Dec 2025

Los Angeles, California, United States • Stanford, California, United States • Aurora, Colorado, United States +4 more locations

RECRUITINGPhase 2192 miles

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT07220577

The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).

Atopic Dermatitis

Novartis Pharmaceuticals84 participantsStarted Nov 2025

Fremont, California, United States • Rockville, Maryland, United States • Hoboken, New Jersey, United States +21 more locations

RECRUITINGPhase 3221 miles

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

Metastatic Castration-resistant Prostate Cancer

Amgen750 participantsStarted Nov 2025

Duarte, California, United States • Duarte, California, United States • Fullerton, California, United States +91 more locations

COMPLETEDPhase 4276 miles

Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

NCT06563102

The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma. Study details include: * The study duration will be up to 15 weeks. * The treatment duration will be 12 weeks. * The visit frequency will be once every 4 weeks, with 3 clinic visits and 2 video calls in total.

AstraZeneca101 participantsStarted Sep 2024

Phoenix, Arizona, United States • Tucson, Arizona, United States • Lancaster, California, United States +13 more locations

RECRUITINGNA308 miles

Use of CereGate Therapy for Freezing of Gait in PD

NCT05292794

A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.

Parkinson DiseaseFreezing of GaitDeep Brain Stimulation

CereGate Inc.41 participantsStarted Apr 2022

Redwood City, California, United States • Aurora, Colorado, United States • Miami, Florida, United States +4 more locations

RECRUITINGPhase 1550 miles

GCC19CART for Patients With Metastatic Colorectal Cancer

NCT05319314

Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.

Colorectal Cancer

Lyell Immunopharma, Inc.30 participantsStarted Aug 2022

Duarte, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +1 more locations

RECRUITINGPhase 2/31021 miles

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

NCT06149559

The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG).

Generalized Myasthenia Gravis

UCB Biopharma SRL12 participantsStarted Jun 2024

Denton, Texas, United States • Bologna, Italy • Milan, Italy +10 more locations

Enrolling By Invitation2022 miles

A Post Approval Multicenter 10 Year Follow-up Observational Trial of Marketed Product - MP01 vs. Surgical Standard of Care (SSOC) Used for the Treatment of Joint Surface Lesions of the Knee

NCT06916728

The purpose of the study is to support market adoption and global market access via collection of long-term effectiveness, safety, and radiographic data. The primary hypothesis is that Marketed Product (MP01) retains its superiority over Surgical Standard of Care (SSOC) at 7 years in term of mean improvement in the overall Knee Injury and Osteoarthritis Outcome Score (KOOS).

Knee InjuriesJoint Surface Knee Lesions

Smith & Nephew, Inc.170 participantsStarted May 2025

La Mesa, California, United States • Antwerp, Belgium • Jerusalem, Israel +5 more locations

PreviousPage 109 of 989Next

Diabetes

in Cleveland

Heart Diseasein Cleveland